Analysis Results of the Regional Registry of Patients with Diffuse Large B-cell Lymphoma: Risk Factors and Chemo-Immunotherapy Issues

Analysis Results of the Regional Registry of Patients with Diffuse Large B-cell Lymphoma: Risk Factors and Chemo-Immunotherapy Issues

Background & Aims. At least one third of patients with diffuse large B-cell lymphoma (DLBCL) are resistant to first-line therapy. R-CHOP chemo-immunotherapy does not yield acceptable results in high-risk patients. Effectiveness of options based either on increasing the dose intensity or on inclu...

Full description

Saved in:
Bibliographic Details
Main Authors: KD Kaplanov, NP Volkov, TYu Klitochenko, IV Matveeva, AL Shipaeva, MN Shirokova, NV Davydov, EG Gemdzhian, DS Abramov, DM Konovalov, GL Snigur, NA Red’kina
Format: Article
Language:Russian
Published: Practical Medicine Publishing House 2019-03-01
Series:Клиническая онкогематология
Subjects:
diffuse large b-cell lymphoma
r-chop
chemoimmunotherapy
survival
pharmacoeconomics
markov model
life years gained (lyg)
incremental cost-effectiveness ratio (icer)
Online Access: http://bloodjournal.ru/wp-content/uploads/2019/03/5-1.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://bloodjournal.ru/wp-content/uploads/2019/03/5-1.pdf

Similar Items